<DOC>
	<DOCNO>NCT01943019</DOCNO>
	<brief_summary>Approximately one third patient schizophrenia show poor response standard treatment antipsychotic medication . This treatment resistant group patient represent major challenge everyday psychiatry , consumes disproportionate amount time clinician , result considerable cost society government . Anecdotal evidence suggest enzyme dipeptidyl peptidase IV ( DPPIV ) may alter patient schizophrenia , high level DPPIV enzyme activity note . We postulate may play role neuropathology schizophrenia patient inhibit DPPIV enzyme activity DPPIV inhibitor linagliptin , able improve even ameliorate symptom schizophrenic patient . However , yet study potential inhibitor schizophrenia patient . A pilot study thus propose evaluate potential DPPIV inhibitor , linagliptin adjunct schizophrenia patient non-responsive treatment , establish feasibility large trial .</brief_summary>
	<brief_title>Linagliptin Schizophrenia Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>18 year age Diagnosis schizophrenia . Clinically stable antipsychotic regimen last 3 month A total score 80 great baseline Positive Negative Syndrome Scale Competent willing provide write , informed consent History substance dependence within past 2 month Existing relevant physical health problem : uncontrolled cardiovascular disease impair liver/ renal function History diabetes History hepatic biliary disease / biliary obstruction A serious suicide/homicide risk opinion investigator Known allergy linagliptin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>